Deborah Wexler, MD, MsC

Institution: Massachusetts General Hospital
Research: Clinical effectiveness in type 2 diabetes
Grants & Publications: Harvard Catalyst
Categories: MGH

Through her research and mentorship, Dr. Wexler aims to define and achieve optimal treatment, quality of care, and quality of life for patients with type 2 diabetes using epidemiologic, clinical trial, and implementation science methodologies and through development and dissemination of guidelines and standards of care. Her expertise in this area is reflected in national leadership roles as a member of the American Diabetes Association’s Professional Practice Committee 2014-2016 and as one of five Americans invited by the ADA to draft the 2018 ADA-EASD Position Statement on Management of Hyperglycemia in Diabetes. She is currently the primary mentor of two endocrinology fellows and two junior faculty members, and a co-mentor to other fellows and junior faculty. She led the development of the MGH Diabetes Center research registry and supervises its use to promote effective recruitment into clinical trials and consults extensively with colleague to share approaches to effective recruitment and care model implementation, having successfully evaluated and implemented new care models in diabetes over the course of the last decade. She is now launching two major PCORI-funded projects.

1) GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study Role: MGH Site Principal Investigator; Member of the Executive Committee, and co-chair of the Outcomes Committee. This 37-site trial, one of the NIDDK’s major clinical trial initiatives in this decade, will evaluate the long-term metabolic and clinical effects of four classes of drugs in combination with metformin for the treatment of type 2 diabetes. It will answer the major pressing clinical questions in treatment of type 2 diabetes while also addressing novel pathophysiologic and cost-effectiveness hypotheses.
2) REAL HEALTH-Diabetes Study. This project adapted and implemented a medically supervised, evidence- based group lifestyle change program in usual care and found that it yielded clinically significant weight loss.
3) Comparative effectiveness of diabetes medications in observational databases. Complementing her work on GRADE, Dr. Wexler is collaborating with Elisabetta Patorno, of the Division of Pharmacoepidemiology at BWH, to conduct a PCORI funded analysis addressing this question using real world evidence.
4) Comparative effectiveness of SGLT2 inhibitors, GLP-1 Receptor agonists, or their combination, a pragmatic comparative effectiveness trial. Dr. Wexler is co-leader of the clinical coordinating center of PRECIDENTD (Everett BM, PI).